Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

Lung cancer is the leading cause of cancer-related deaths worldwide [1,2]. Over the past decade, significant improvements have been made in understanding cancer pathogenesis and many new drugs have been developed for the treatment of non-small cell lung cancer (NSCLC) without actionable oncogenic drivers. Immune checkpoint inhibitors have revolutionized lung cancer therapy in the first line setting [3 –5] (alone or in combination with cytotoxic agents) regardless of histology and, in the second line, of PD-L1 expression, being these drugs a new standard of care for selected patients [6–9].

Source: Lung Cancer - June 26, 2019 Category: Cancer & Oncology Authors: Enrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, Rita Chiari, Francesco Grossi, Marcello Tiseo, Francesco Di Costanzo, Angelo Delmonte, Gianpiero Romano, Domenico Galetta, Vieri Scotti, Vanesa Gregorc, Salvatore Pisconti, Giovanni Luca Ceres Source Type: research